Literature DB >> 3020156

The nucleotide sequence of a type 3 poliovirus isolated during a recent outbreak of poliomyelitis in Finland.

P J Hughes, D M Evans, P D Minor, G C Schild, J W Almond, G Stanway.   

Abstract

We have cloned and sequenced the complete genome of a strain of poliovirus type 3 (23127) isolated during an outbreak of poliomyelitis in Finland. The genome is 7435 nucleotides long excluding the 3' poly(A) stretch and is 95.5% homologous at the amino acid level to the previously sequenced type 3 strain, P3/Leon/37. The most striking feature of the presented sequence is the extent of amino acid substitutions relative to P3/Leon/37 and other type 3 strains in areas of known antigenic importance. The major antigenic determinant for virus neutralization (site 1), located at residues 89 to 100 of VP1, has three amino acid substitutions and there are six substitutions in site 3, a composite site made up of sequences from VP1 and VP3. The variation in these regions probably accounts for the observed unusual antigenicity and may explain why the virus was able to spread in a well-vaccinated community. Sequence comparisons imply that the virus is not derived from the currently used live attenuated vaccine.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3020156     DOI: 10.1099/0022-1317-67-10-2093

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  16 in total

1.  Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion.

Authors:  J Martín; G Dunn; R Hull; V Patel; P D Minor
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region.

Authors:  Cara Carthel Burns; Jing Shaw; Ray Campagnoli; Jaume Jorba; Annelet Vincent; Jacqueline Quay; Olen Kew
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

Review 3.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

4.  Group-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residue at positions of codon degeneracy.

Authors:  D R Kilpatrick; B Nottay; C F Yang; S J Yang; M N Mulders; B P Holloway; M A Pallansch; O M Kew
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

5.  Restricted variability of a 17 nucleotide stretch within the 5'-noncoding region of poliovirus genome.

Authors:  T Pöyry; L Kinnunen; T Hovi
Journal:  Epidemiol Infect       Date:  1989-12       Impact factor: 2.451

6.  The sequence of the coxsackievirus A 21 polymerase gene indicates a remarkably close relationship to the polioviruses. Brief report.

Authors:  P J Hughes; A Phillips; P D Minor; G Stanway
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

7.  Mutation of a single conserved nucleotide between the cloverleaf and internal ribosome entry site attenuates poliovirus neurovirulence.

Authors:  Nidia De Jesus; David Franco; Aniko Paul; Eckard Wimmer; Jeronimo Cello
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

8.  Poliomyelitis in North America: the disease is not dead yet.

Authors:  E G Morrison; J A Embil
Journal:  CMAJ       Date:  1987-12-15       Impact factor: 8.262

9.  Membrane interaction of small N-myristoylated peptides: implications for membrane anchoring and protein-protein association.

Authors:  M B Sankaram
Journal:  Biophys J       Date:  1994-07       Impact factor: 4.033

10.  Identification of vaccine-related polioviruses by hybridization with specific RNA probes.

Authors:  L De; B Nottay; C F Yang; B P Holloway; M Pallansch; O Kew
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.